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Abstract
Background: Our aim was to detect lymphatic endothelial marker podoplanin, lymphatic vessel
endothelial hyaluronan receptor-1 (LYVE-1) and vascular endothelial growth factor receptor-3
(VEGFR)-3 and study the prognostic relevance of lymphangiogenesis in non-small cell lung cancer
(NSCLC).
Materials: 82 paraffin-embedded tissues and 40 fresh frozen tissues from patients with NSCLC
were studied. Tumor samples were immunostained for the lymphatic endothelial markers.
Lymphangiogenesis was assessed by immunohistochemical double stains for Podoplanin and Ki-67.
The prognostic relevance of lymphangiogenesis-related clinicopathological parameters in NSCLC
was evaluated.
Results: We found that the number of podoplanin positive vessels was correlated positively with
the number of LYVE-1 positive vessels. Most of VEGFR-3 positive, few of LYVE-1 positive and none
of podoplanin positive vessels were blood vessels. Peritumoral lymphatic vessel density (ptLVD),
pathologic stage, lymph node status, lymphatic vessel invasion (LVI), vascular endothelial growth
factor-C (VEGF-C) expression and Ki-67 index of the endothelium cells of the micro lymphatic
vessels (Ki67%) were associated significantly with a higher risk of tumor progress. ptLVD,
pathologic stage, lymph-node metastasis and Ki67% were independent prognostic parameters for
overall survival.
Conclusion: Podoplanin positive ptLVD might play important roles in the lymphangiogenesis and
progression of NSCLC. Patients with high podoplanin+ ptLVD have a poor prognosis.
Background
The major cause of death from malignant tumors includ-
ing non-small cell lung cancer (NSCLC) is dissemination
of the primary tumor, leading to formation of metastases.
Spread to regional lymph nodes is often the first step of
generalization. Thus, the presence of lymph node metas-
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tasis represents a major criterion for evaluating the prog-
nosis of NSCLC patients. Tumor-associated
lymphangiogenesis are considered as the main route for
lymphatic metastasis. And lymphovascular invasion (LVI)
of tumor cells is a prerequisite for the dissemination via
the lymphatic system. However, Studies of lymphatic ves-
sels and lymphogenic metastasis have been hampered by
the lack of specific lymphatic markers. Recently several
markers for normal and tumor-associated lymphatic ves-
sels have provided tools for a detailed analysis of lym-
phangiogenesis in human lung cancers. These markers
include vascular endothelial growth factor C and D
(VEGF-C, VEGF-D) [1,2], vascular endothelial growth fac-
tor receptor-3 (VEGFR-3) [3-6], the lymphatic vessel
endothelial hyaluronan receptor-1 (LYVE-1) [7] and
glomerular podocyte membrane mucoprotein podo-
planin [8]. Podoplanin had been speculated as a specific
lymphatic endothelial marker in many solid tumors
including breast cancer, cervical cancer, Ovarian Cancer
and NSCLC [9,10]. However, there are some contradictory
results between different studies and many problems to
be clarified. For example, VEGFR-3 is expressed not only
in lymphatic endothelium in normal adult tissue, but also
in vascular endothelium in tumor tissue. Therefore, using
VEGFR-3 as a marker of tumor lymph vessel may lead to
loss of accuracy in lymphatic vessel density (LVD) count-
ing [11]. LYVE-1 was thought to be restricted to lymphatic
vessels [12]. However, LYVE-1 was also found in normal
hepatic blood sinusoidal endothelial cells and macro-
phage [13,14]. The specificity of LYVE-1 for lymphatic
endothelial cells (LECs) has been questioned by some
investigators [15]. Futhermore, Padera [16] showed that
approximately 10% of LYVE-1+ vessels were indeed blood
vessels, suggesting that LYVE-1 alone is not suitable for the
detection of functional lymphatic vessels. Until recently,
tumorologists have recognized podoplanin as the most
specific marker for lymphatic endothelium. And a double
immunostaining with the D2–40 and anti-Ki67 mono-
clonal antibody is used as the standard method for the
assessment of lymphangiogenesis in solid tumors[17].
Thus, the aim of this study was to detect Lymphangiogen-
esis and find the relationship between clinicopathological
parameters, such as LVD, lymph-node metastasis, VEGF-




This retrospective study included 82 patients with NSCLC
who underwent either lobectomy or pneumonectomy at
Xinqiao Hospital between January 1995 and November
2004. All of these patients have complete clinical and
pathological records. None of the patients received pre-
surgical radio- or chemotherapy before operation. Follow-
up was made to August 31, 2005, by phone call, letter
inquiry and visiting census register agency. During the fol-
low-up period, there were 35 patients still alive and 47
deaths. Patients who were lost to follow up or died for
noncancer-related reasons were excluded. Pathological
stage was reevaluated and determined with the present
TNM classification as revised in WHO 2004 classification
criteria. Formalin-fixed, paraffin-embedded NSCLC tis-
sues were retrieved from the files of our pathology depart-
ment. Tissue blocks containing a representative fraction of
the tumor and the tumor-lung parenchyma interface were
used. Operative tissues embedded with paraffin from the
82 patients with NSCLC. In addition, the fresh frozen
operation tissues of 40 NSCLC patients from Xinqiao and
Daping hospital were used for LYVE-1 immunohisto-
chemistry and H&E staining (LYVE-1 expression was only
on the fresh frozen sections, not on paraffin sections). The
study was approved by the Ethics Committee (Faculty of
Medicine, Third Military Medical University).
Immunostaining for LYVE-1, CD31, VEGFR-3, podoplanin, 
VEGF-C and Vessel Counts
Immunohistochemical stainings were done on tissues
fixed in 10% neutral buffered formalin and embedded in
paraffin. Paraffin sections (5 μm) were dewaxed and rehy-
drated. For light microscopy, peroxidase was quenched
with methanol and 3% H2O2 for 15 minutes. Antigen
retrieval was done in 0.1 mol/L citrate buffer (pH = 6) in
an 800W microwave for 15 minutes (the step was omitted
in fresh frozen section staining). After washing in PBS, the
following primary antibodies were used: rabbit polyclo-
nal anti-human LYVE-1 (10 μg/ml, Angiobio Co, USA),
rabbit monoclonal anti-human podoplanin (1:100,
Angiobio Co, USA), mouse monoclonal anti-human
CD31 (ready to use, Zhongshan, Beijing), rabbit polyclo-
nal anti-human VEGFR-3, VEGF-C (ready to use, Zhong-
shan, Beijing). All primary and secondary IgGs were
diluted in PBS. Isotypic controls were performed for mon-
oclonal as well as use of non immune serum for polyclo-
nal antibodies (same concentrations as the test
antibodies). Determination of LVD (assessed by immu-
nostaining for podoplanin, LYVE-1, VEGFR-3) and CD31
microvessel density (MVD) was performed as suggested
by Weidner [18]. Briefly, the immunostained sections
were first scanned at a low magnification (40×), and the
areas with the greatest number of microvessels (vessel
"hot spots") were selected for further evaluation. The
microvessel count was then determined by counting all
immunostained vessels in five separate hot spots at a high
magnification (×200). The average number of LVD or
MVD in the five selected vessel hot spots was then calcu-
lated. In immunostainings for CD31, podoplanin, LYVE-
1 and VEGFR-3, any positive cell clusters were considered
as endothelial cells and countable microvessels. LVI was
considered evident if at least one tumor cell cluster was
clearly visible inside the podoplanin-stained vascularJournal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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space [19]. Peritumoral lymphatic vessels were defined as
LYVE-1/podoplanin/VEGFR-3-positive vessels within an
area of 100 μm from the tumor border. Intratumoral lym-
phatic vessels were defined as LYVE-1/podoplanin/
VEGFR-3-positive vessels located within the tumor mass
and not confined by invagination of normal tissue [20].
Double immunostaining with podoplanin and Ki-67
Immunohistochemical double stains for Podoplanin and
Ki67 were done on serial sections according to Van den
Eynden's method [21]. Podoplanin and Ki-67 was stained
by D2–40 and anti-Ki67 monoclonal antibody, respec-
tively. (Angiobio & Beijing Zhongshan Jinqiao Biotech-
nology Co., respectively) Histastain™-DS double
immunostaining kit was purchased from Zymed. In brief,
sections were first incubated with primary antibody, i.e.
podoplanin (dilution 1:200), and biotinized secondary
antibody, which was visualized with the Envision + dual
link system (Dakocytomation, Carpinteria, CA, USA). A
second primary antibody, i.e. Ki67 (dilution 1:100) was
then applied and visualized with the Envision G/2 sys-
tem/AP (Dakocytomation, Carpinteria, CA, USA). Micro
lymphatic vessels were brownish yellow after staining,
while the nucleus of the proliferating endothelium cells of
the micro lymphatic vessels appeared red. Ki-67 index of
the endothelium cells of the micro lymphatic vessels
(Ki67%) was calculated according to Wulff et al [22].
Statistical Analysis
Correlations between podoplanin, VEGFR-3, LYVE-1 and
the vessel numbers as continuous variables were used to
assess CD31-positive vessel counts with the Spearman
rank correlation test. Categorical data were compared by
the χ2 or Fishers' exact probability test. Distribution was
normal or with Mann Whitney U test if the sample distri-
bution was asymmetrical. The relationship between
lymph vessel variables and lymph node status was ana-
lyzed by one-way ANOVA, followed by the Neuman-
Keuls test. Overall survival intervals were determined as
the time period from initial diagnosis to the time of death.
Overall survival analyses were done using the Kaplan-
Meier method. The comparison between survival func-
tions for different strata was assessed with the log-rank
statistic. Multivariate analysis of prognostic factors was
done using Cox's regression model. Differences were con-
sidered significant when P ≤ 0.05. All statistical analyses
were done using the statistical package spss13.0.
Results
CD31, VEGFR-3, LYVE-1, VEGF-C Expression in NSCLC
Numerous intratumoral and peritumoral vessels could be
observed in each NSCLC tumor irrespective of histologic
grade and pathologic stage. CD31 was positive in
endothelial cell plasma in micro vessels, appeared yellow
granular. Micro vessels of tumor tissues were mainly
located at intra-tumor and peritumoral area. However,
large blood vessels with muscular coat were also positive
stained for CD31 (Fig. 1a). VEGFR-3 showed an expres-
sion similar to CD31. VEGFR-3 positive vessels included
not only dilated and irregular thin-walled lymphatic ves-
sels, but also blood vessels containing erythrocytes and
large blood vessels with smooth muscle (Fig. 1b). LYVE-1
was positively stained in endothelial cell plasma and
plasma membrane in micro vessels, appeared yellow
granular (Fig. 1c). However, few LYVE-1 positive vessels
were large blood vessels with smooth muscle, and tumor
embolus were observed in their muscular layer and lumen
(Fig. 1d). VEGF-C positive substance in tumor tissue was
yellow fine granular, mainly located in tumor cell plasma.
Positive cells were dispersed, limited locally or in small
patches (Fig. 1e). In the para-tumor normal bronchia,
VEGF-C expression was dispersed in columnar epithelium
cells (Fig. 1f).
Podoplanin Expression in NSCLC
Podoplanin expression was mainly present in thin-walled
(lymphatic) structures. Podoplanin was positive in
endothelial cell plasma in thin-walled lymph vessel,
appeared yellow granular. Podoplanin-positive lymph
vessels were commonly located around the tumor or at
the tumor boundary, mainly located at adenocarcinoma
interstitium, peri-tumor area of squamous cell carcinoma
and interstitium of large cell lung cancer (Fig. 2a, b, c). 4
cases of squamous cell carcinoma also demonstrated
podoplanin expression in cancer cell plasma (data not
shown). Moreover, we cut serial sections of lung cancer
tissue, and stained them with podoplanin, CD31 and
VEGFR-3, respectively. The red arrow in Fig. 2d indicates
podoplanin-negative blood vessels. Black arrow in Fig. 2d
indicates podoplanin-positive lymph vessel. While in Fig.
2e and 2f, the same region was positively stained for
CD31 and VEGFR-3, indicating that VEGFR-3 was also a
marker of blood vessels.
Correlation analysis of podoplanin, LYVE-1, VEGFR-3 and 
CD31
In 82 paraffin-embedded NSCLC tissues, the mean
number of podoplanin+ vessels was 21.5 ± 8.4 (range 7.4–
43.6). The mean number of CD31 and VEGFR-3+ vessels
was 51.4 ± 11.1 (range 30.0–77.2) and 30.2 ± 16.8 (range
0–46.6), respectively. No substantial association was
found between the number of podoplanin+ vessels and
CD31+ or VEGFR-3+ vessels (the Spearman rank correla-
tion coefficient r = -0.171, P = 0.124; r = 0.003, P = 0.979,
respectively). In contrast, high counts of VEGFR-3+ vessels
were strongly associated with high CD31+ vessel counts (r
= 0.331, P = 0.002), which showed most VEGFR-3+ vessels
were microvalscular vessels not lymphatic vessels.Journal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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In addition, in 40 frozen NSCLC tissues, the mean
number of LYVE-1+ vessels was 19.9 ± 9.0 (range 5.2–
48.0). The mean number of CD31 and podoplanin+ ves-
sels was 52.3 ± 10.9 (range 34.4–71.2) and 22.1 ± 8.1
(range 6.6–44.6), respectively. No substantial association
was found between the number of CD31+ vessels and
LYVE-1 or podoplanin+ vessels (r = 0.009, P = 0.957; r =
0.059, P = 0.717, respectively). In contrast, high counts of
LYVE-1+ vessels were strongly associated with high podo-
planin+ vessel counts (r = 0.525, P = 0.001). With the
results of morphology above mentioned, LYVE-1+ vessels
were most lymphatic vessels, but few of them were micro
vessels.
VEGF-C expression in NSCLC tissue and its relation to lymph node 
metastasis
Carcinoma VEGF-C expression was classified either as
positive (n = 61, ≥10% of the carcinoma cells expressed
VEGF-C) or negative (n = 21, absent expression or expres-
sion in < 10% of the carcinoma cells). Among the 82
NSCLC tissues, 61 were VEGF-C positive, 21 were nega-
tive, indicating a positive expression rate of 74.4% (61/
82). The positive expression rate was significantly higher
in the lymph node positive group (93.2%, 41/44) than in
the lymph node negative group (52.6%, 20/38) (P  =
0.000) (Fig. 3a). ptLVD of patients was significantly
higher in the VEGF-C positive group than in the VEGF-C
negative group (23.1 ± 8.5 vs 15.6 ± 4.2, P = 0.000). How-
ever, intratumoral lymphatic vessel density (itLVD) values
of the two groups showed no significant difference (10.7
± 5.3 vs 10.4 ± 4.7, P = 0.820) (Fig. 3b). According to
spearman correlation analysis, VEGF-C expression was
positively correlated with ptLVD and lymph node metas-
tasis (r = 0.367, P = 0.001; r = 0.463, P = 0.000). Moreover,
ptLVD was also positively correlated with lymph node
metastasis(r = 0.354, P = 0.001).
Associations of Lymphangiogenesis with 
Clinicopathological Parameters in NSCLC
Double immunostaining with podoplanin and Ki-67 was
performed for lymphogenesis analysis (Figure 4). Micro
lymphatic vessels were brownish yellow after staining,
while the nucleus of the proliferating endothelium cells of
the micro lymphatic vessels appeared brownish red (indi-
cated by the red arrow). Cancer embolus was detected in
lymphatic vessels(Figure 4a).
Immunohistochemical analysis of different markers Figure 1
Immunohistochemical analysis of different markers.Journal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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Immunostaining for podoplanin in nsclc tissues Figure 2
Immunostaining for podoplanin in nsclc tissues.
Prognosis analysis of vegf-c expression Figure 3
Prognosis analysis of vegf-c expression.Journal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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Double immunostaining with podoplanin and ki-67 Figure 4
Double immunostaining with podoplanin and ki-67.
Table 1: Association of LVD and LVI with other clinicopathological parameters
Clinicopathological Parameters Cases ptLVD itLVD LVI
(-/+)
Mean Survival Time 
(x ± s)
median survival time
Age (y)* 55 42 22.1 ± 8.9 10.1 ± 5.1 17/25 1567 ± 138 1658
<55 40 20.8 ± 7.9 11.2 ± 5.1 21/19 1856 ± 241 1864
Gender male 63 21.0 ± 7.9 11.2 ± 4.9 27/36 1795 ± 183 1658
female 19 23.2 ± 9.9 8.7 ± 5.5 11/8 1578 ± 214 1577
Histologic type Squamous cell 31 19.7 ± 6.4 9.6 ± 4.6 14/17 1664 ± 189 1972
Adenocarcinoma 41 22.4 ± 9.5 11.0 ± 5.1 20/21 1815 ± 231 1337
Large cell 10 23.4 ± 9.1 12.4 ± 6.1 4/6 1134 ± 156 1118
Tumor differentiation Well-moderate 44 21.3 ± 8.6 10.5 ± 5.4 20/24 2085 ± 220 1900
Poor 38 21.7 ± 8.3 10.8 ± 5.0 18/20 1325 ± 154 1118
Pathologic N stage N1–2 44 24.2 ± 8.9# 10.6 ± 5.4 15/29# 943 ± 107# 674
N0 38 18.4 ± 6.7 11.7 ± 4.7 22/16 2725 ± 213 2545
Pathologic T stage T2–3 51 20.9 ± 8.6 11.4 ± 5.2 21/30 1449 ± 149 1223
T1 31 22.5 ± 8.0 9.5 ± 4.8 17/14 1875 ± 172 1775
BVI BVI+ 39 23.2 ± 9.8 9.8 ± 4.3 21/18 1321 ± 146 1117
BVI- 43 19.9 ± 6.6 11.3 ± 5.7 12/21 2083 ± 230 2031
ptLVD* High(≥19.9) 41 / 12.7 ± 5.6 13/28# 1171 ± 153# 772
Low(<19.9) 41 / 12.2 ± 4.9 25/16 2378 ± 224 2057
itLVD* High(≥10.2) 46 22.9 ± 7.4 / 23/23 1749 ± 229 1577
Low(<10.2) 36 23.3 ± 6.7 / 15/21 1675 ± 162 1658
LVI LVI+ 46 24.0 ± 9.3# 10.9 ± 5.4 / 1212 ± 125# 1006
LVI- 36 18.2 ± 5.8 10.3 ± 4.7 / 2433 ± 245 2123
Pathologic stage I+II 48 19.4 ± 7.6# 10.8 ± 4.9 26/22# 2501 ± 202# 2115
III+IV 34 24.5 ± 8.7 10.4 ± 5.4 11/23 800 ± 105 621
VEGF-C Positive 61 23.1 ± 8.5# 10.6 ± 5.0 24/37# 1519 ± 173# 1117
Negative 21 16.9 ± 6.0 10.7 ± 5.7 14/7 2232 ± 194 1981
Ki67/%* High(≥3.56) 50 24.2 ± 9.2# 12.9 ± 4.4 21/29# 1322 ± 135# 1109
Low(<3.56) 32 17.2 ± 4.8 13.3 ± 5.0 21/11 2431 ± 235 2024
*Cutoff value is median value. #Correlation is statistically significant.
(BVI: Blood vessel invasion, LVI: lymphatic vessel invasion, ptLVD: peritumoral lymphatic vessel density, itLVD: intratumoral lymphatic vessel 
density, Ki67/%: Ki-67 index of the endothelium cells of the micro lymphatic vessels)Journal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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The clinic significance was studied by analyzing the peri-
tumoral and intratumoral lymphangiogenesis, various
pathological parameters and follow-up data in 82 cases of
NSCLC (Table 1). We divided LVD into high LVD Group
and low LVD Group according to median. Then the differ-
ences was analyzed one by one between ptLVD and itLVD
in Age, Gender, Histologic type, Tumor differentiation,
Pathologic N stage, Pathologic T stage, Blood vessel inva-
sion (BVI), LVI, Pathologic stage, VEGF-C expression and
Ki67%. The mean itLVD was 10.2. No difference was
found in any factors between Group high itLVD (n = 46)
and Group low itLVD (n = 36) (P > 0.05 for all analyses).
But ptLVD was different. The median ptLVD was 19.9. No
difference was found in LVI, age, gender, the primary
tumor size, histologic grade and histologic type between
Group high ptLVD (n = 41) and Group low ptLVD (n =
41) (P > 0.05). However, high ptLVD Group showed a sig-
nificant increase than low ptLVD Group in several other
clinicopathological parameters, such as lymph node
metastasis, LVI, pathologic stage, VEGF-C and Ki67%.
Namely, ptLVD was higher in stage III a patients than in
stage I and II (P < 0.01), in LVI positive than in LVI nega-
tive (P = 0.004), in lymph node metastasis than in lymph
node negative (P  < 0.01), in VEGF-C positive than in
VEGF-C negative (P < 0.01) in high Ki67% than in low
Ki67%. ptLVD were associated significantly with a higher
risk for developing LVI and lymph-node metastasis (P <
0.01).
Associations of LVI with Clinicopathological Parameters
Likewise, the relationship was analyzed between LVI and
Age, Gender, Histologic type, Tumor differentiation, Path-
ologic N stage, Pathologic T stage, Blood vessel invasion,
LVI, Pathologic stage, VEGF-C expression and Ki67%
(Table 1). Data showed that LVI were significantly associ-
ated with lymph-node metastasis, ptLVD, Pathologic
stage, VEGF-C expression and Ki67% (P < 0.01), but not
with itLVD, Pathologic T stage and Blood vessel invasion
(BVI).
Lymphangiogenesis and Prognostic factor in NSCLC
The overall survival rate (OS) was 49.3% in 82 NSCLC
cases in five years. The median observation time was 1291
days (ranging from 103 to 3680 days). The Kaplan-Meier
survival rate curve was showed in Fig 5a. Among it, five
year survival rate was 33.5% in LVI+ patients, and 70.0%
in LVI- ones. By log-rank test, it was significantly different
in survival rate curve in Fig 5b (P = 0.0002). Five year sur-
vival rate was 31.0% in high ptLVD patients, and 67.6%
in low ptLVD ones, showing significant difference in sur-
vival rate curve (Fig 5c) (P = 0.0001). Five year survival
rate was 50.0% in high itLVD patients, and 48.7% in low
itLVD ones, showing no significant difference in survival
rate curve (Fig 5d) (P = 0.7045). In univariate survival
analysis, intramural LVD (P  = 0.719), as well as the
patient's age, gender and other clinical and histopatho-
logic parameters had no influence on OS in our collective
(P > 0.05 for all analyses). A significant difference in OS
was found between patients with high and those with low
podoplanin+ ptLVD (groups cut off by LVD median) (P =
0.0001), with and without LVI (P = 0.0002), lymph node
status (P = 0.0000), pathologic stage (P = 0.0000), VEGF-
C expression (P = 0.0054) and Ki67%(P = 0.0001). A mul-
tivariate analysis of these individuals was performed using
the Cox regression Model. ptLVD, pathologic stage,
lymph-node metastasis and Ki67% were independent
prognostic parameters for overall survival (P  = 0.028)
(Table 2). Podoplanin positive ptLVD might play impor-
tant roles in the lymphangiogenesis and progression of
NSCLC. Patients with high podoplanin+ ptLVD have a
poor prognosis.
Discussion
There are many reports about tumor angiogenesis and
poor prognosis in NSCLC. For example, Carcinoembry-
onic antigen-related cell adhesion molecule 1 (CEACAM-
1) has recently been reported to be implicated in cancer
development and progression. The elevated CEACAM-1
expression and increased MVD, was an unfavorable prog-
nosis in NSCLC [23]. It has also been reported that high
CD34+ MVD and tumour vessel invasion are more closely
Table 2: Multivariate analysis of various prognostic factors in patients with NSCLC
Univariate Multivariate
Prognostic factor P value β P value Relative Risk (95%) CI)
ptLVD (high/low) 0.0001 0.828 0.003 2.288 (1.182–4.428)
Pathologic stage(I+II/III+IV) 0.0000 1.310 0.003 3.708 (1.581–8.694)
Pathologic N stage (N0/N2–3) 0.0000 1.218 0.010 3.382 (1.344–8.511)
LVI (-/+) 0.0002 0.714 0.052 2.041 (0.993–4.196)
VEGF-C(-/+) 0.0054 -0.365 0.490 0.694 (0.246–1.958)
Ki67% 0.0012 0.726 0.032 2.067 (1.026–4.161)
(LVI: lymphatic vessel invasion, ptLVD: peritumoral lymphatic vessel density, Ki67/%: Ki-67 index of the endothelium cells of the micro lymphatic 
vessels)Journal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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related to poor survival than the other neoangiogenetic
factors in stage IB-IIA NSCLC [24]. In recent years, with
the identification of lymphatic endothelial growth factor-
C (VEGF-C), VEGF-D and lymphatic endothelial markers
including LYVE-1, VEGFR-3 and podoplanin, lymphang-
iogenesis has become one of the highlights in the field of
metastasis in NSCLC. Active lymphangiogenesis is ongo-
ing within sentinel lymph node (SLN) from NSCLC
patients, even before metastasis. This lymphangiogenesis
may be promoted by upregulation of VEGF121, which
may in turn act in part through induction of VEGF-C [25].
Kadota [26] also showed that lymphangiogenesis, specifi-
cally Micro-LVD was independently associated with poor
prognosis of NSCLC patients. However, these researches
can not indicate which LVD status was associated with
prognosis of NSCLC patients. What is more, a Meta anal-
ysis has been finished [27]. 17 centers provided data for
3200 patients, 2719 of which were included in the analy-
sis. For microvessel density counts obtained by the Chalk-
ley method, the HR for death per extra microvessel was
1.05 (95% CI 1.01–1.09, P = 0.03) when analyzed as a
continuous variable. For microvessel density counts
obtained by the all vessels method, the HR for death per
ten extra microvessels was 1.03 (0.97–1.09, P = 0.3) when
Survival analysis of clinicopathological parameters Figure 5
Survival analysis of clinicopathological parameters.Journal of Experimental & Clinical Cancer Research 2009, 28:21 http://www.jeccr.com/content/28/1/21
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analyzed as a continuous variable. Microvessel density
does not seem to be a prognostic factor in patients with
non-metastatic surgically treated NSCLC. These conclu-
sions contradict each other. Therefore, the methodology
used to assess prognostic factors should be assessed care-
fully.
Positive correlation was found between the number of
podoplanin positive vessels and the number of LYVE-1
positive vessels, while counts of VEGFR-3 positive vessels
were correlated with CD31 positive vessel counts. Most of
VEGFR-3 vessels, few of LYVE-1 and none of podoplanin
positive vessels were blood vessels by observation of light
microscope. The results were in accordance with Petri
Bono's [28]. In specimens investigated in our study podo-
planin expression was restricted to thin-walled lymph ves-
sels with a single endothelial layer. Blood vessels
containing red blood cells remained unstained. Podo-
planin+ lymph vessels were almost peritumoral, not intra-
tumoral. Lymph vessels could not form in the tumor
because of low expression of lymphatic vessel growth fac-
tor and high expression of lymph vessel inhibitor factor in
the tumor. Furthermore, high interstitial pressure in the
tumor was caused with an increase size of lesions [29].
Our research also shows that podoplanin+ ptLVD is asso-
ciated with lymphatic metastasis, Pathologic stage and
Ki67%, and not with histologic type or Tumor differenti-
ation. We presumed that high density of lymph vessels
could increase cancer cells to contact with, and invade
into lymph vessels, promote lymphatic metastasis and
tumor progress. So, podoplanin+ ptLVD is an independent
prognostic parameter indeed. Patients with high podo-
planin+ ptLVD have a poor prognosis. The result is consist-
ent with the previous research. Saijo [30] showed the
recurrence-free survival (RFS) time of patients with high
Lymphatic permeation (ly 2) was significantly shorter
than that of no Lymphatic permeation (ly 0) patients (P <
0.0001), and low Lymphatic permeation(ly 1) patients (P
= 0.0028). A significant difference in RFS time was also
observed between the ly 0 patients and the ly 1 patients (P
= 0.0025). RFS time of the ly 0 patients was significantly
longer than that of the ly 1 plus ly 2 patients (P < 0.0001).
Saijo only studied Lymphatic permeation (ly) in Lym-
phangiogenesis and prognosis of patients with NSCLC.
Our study further shows that podoplanin+ ptLVD not
itLVD is the prognostic parameter. Podoplanin+ ptLVD
could also be useful to be a new antitumor target. How-
ever, these observations are based only on retrospective
analysis of a small case series and further evaluation with
a larger number of cases is necessary.
Conclusion
Podoplanin is the most specific lymphatic endothelial
marker. ptLVD and lymph-node metastasis might play
important roles in the onset and progression of NSCLC.
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